Dr. Paul Walfish on PD-1 Expression in Thyroid Cancer
Paul Walfish, MD, professor emeritus at the University of Toronto School of Medicine, senior consult Mount Sinai Hospital discusses programmed death ligand 1 (PD-1) expression in aggressive metastatic papillary thyroid cancer.
Japanese Clinical Trial Aims to Standardize Anaplastic Thyroid Carcinoma Treatment
A Japanese research team attempted to standardize therapy for anaplastic thyroid carcinoma by assessing the feasibility and efficacy of weekly paclitaxel administration.
Immunotherapy May Lead to Abnormal Thyroid Function in Patients With Cancer
A comprehensive review of patients receiving pembrolizumab has found an incidence of abnormal thyroid function tests as high as 15%.
PD-L1 Strongly Correlates With Papillary Thyroid Cancer Aggressiveness
Investigators at the Mount Sinai School of Medicine, Toronto, Canada, have been working on a potential correlation for aggressiveness and/or disease-free survival in thyroid cancer patients.
Dr. Michael Tuttle on Dosimetry Versus Empiric Dosing Radioactive Iodine Treatment
Michael Tuttle, MD, endocrinologist Memorial Sloan Kettering (MSK), discusses best management approaches to radioactive iodine treatment in patients with radioiodine avid distant metastases from differentiated thyroid cancer.
Next-Generation Sequencing Suggests BRAF With TERT Comutation Occurs in Advanced Well-differentiated Thyroid Cancer
Researchers have posited that well-differentiated thyroid cancers harbor distinct molecular pathological profiles that may be useful as prognostic indicators of future aggressiveness.
Sub-Centimeter Thyroid Nodule Size May Not Offer Good Prognostic Indicator for Biopsy
The rising overall risk of all sizes of malignant thyroid cancer has made clinicians question whether or not sub-centimeter thyroid nodules should also be biopsied.
Molecular Profiling of Medullary Thyroid Cancer Identifies Prognostic Markers for Vandetanib
While medullary thyroid cancer is not common as other thyroid cancers, it does have a poorer prognosis than these more common forms of metastatic thyroid cancer.
Dr. Delivanis on Pembrolizumab-Induced Thyroiditis
Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.
Anti-BRAF V600E Plus Antiangiogenesis May Possess Greater Activity Against Metastatic Papillary Thyroid Carcinoma
BRAF V600E is essential to the survival of many tumors and has been the focus of targeted therapeutics like a new BRAF V600E-selective inhibitor, which has been used for papillary thyroid carcinomas.
Pazopanib Treatment Outcome Not Predicted by Thyroglobulin Status
Keith Bible, MD, PhD, Mayo Clinic professor of oncology goes into detail about the current status of using VEGFR tyrosine kinase inhibitors to treat thyroid cancer.
Cabozantinib Shows Promise in Second- and Third-line Differentiated Thyroid Cancer
Cabozantinib, an oral multikinase inhibitor, showed promise as second- or third-line therapy in patients with advanced differentiated thyroid cancer (DTC).
Dr. Sylvia Asa on Thyroid Cancer Genotyping
Dr. Sylvia Asa, MD, PhD, pathologist with the Toronto General Hospital/Research Institute (UHN) and a professor at the University of Toronto, discusses genotyping and the role it can play in diagnosing and selecting targeted treatments for thyroid cancer.
Survey Reveals Wide Variation in the Treatment of Thyroid Nodules
Dr. Nicole O. Vietor presented a report assessing practice discordances related to previously published guidelines published from the American Thyroid Association and the American Association of Clinical Endocrinologists.
Lenvatinib Extended Progression-Free Survival in Patients With Metastasis
Patients in a lenvatinib treatment arm with radioiodine-refractory differentiated thyroid cancer and certain metastasis experienced a much better overall median progression-free survival compared with a placebo arm.
2 Commerce Drive Cranbury, NJ 08512